Merck Sharp & Dohme Corp. - Page 1

GC Cell's shares drop as MSD terminates $1.8B deal with Artiva

July 2, 2024

Merck Sharp & Dohme Corp. (MSD), known as Merck & Co. Inc. in the U.S. and Canada, terminated its potential $1.86 billion deal with San Diego-based Artiva Biotherapeutics Inc. for novel chimeric antigen receptor-natural killer cell therapies. GC Cell disclosed news of the terminated deal on the Korea Exchange near market close of June 25, saying it was notified by Artiva after the decision was reached by MSD’s internal decision makers.

GC Cell's shares drop as MSD terminates $1.8B deal with Artiva

June 27, 2024

By Marian (YoonJee) Chu

Merck Sharp & Dohme Corp. (MSD), known as Merck & Co. Inc. in the U.S. and Canada, terminated its potential $1.86 billion deal with San Diego-based Artiva Biotherapeutics Inc. for novel chimeric antigen receptor-natural killer cell therapies. GC Cell disclosed news of the terminated deal on the Korea Exchange near market close of June 25, saying it was notified by Artiva after the decision was reached by MSD’s internal decision makers.

Cancer

Merck Sharp & Dohme patents new adenosine A2A and A2B receptor antagonists

Sep. 8, 2023

Merck Sharp & Dohme Corp. has disclosed adenosine A2A (ADORA2A) and/or A2B (ADORA2B) receptor antagonists reported to be useful for the treatment of cancer.

Ocular

Merck Sharp & Dohme divulges new KLKB1 inhibitors

Aug. 28, 2023

Merck Sharp & Dohme Corp. has synthesized plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, wet macular degeneration (exudative) and uveitis.

Infection

Merck Sharp & Dohme patents new DNA polymerase inhibitors to treat herpes virus infection

July 11, 2023

Merck Sharp & Dohme Corp. has disclosed pyrazolopyrimidine derivatives acting as DNA polymerase inhibitors reported to be useful for the treatment of herpes virus infection.

Neurology/Psychiatric

Merck Sharp & Dohme reports RIPK1 inhibitors for ALS and inflammatory disorders

May 23, 2023

Research at Merck Sharp & Dohme Corp. has led to the development of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS) and inflammatory disorders.

Neurology/Psychiatric

Merck Sharp & Dohme patents new RIPK1 inhibitors

May 19, 2023

Merck Sharp & Dohme Corp. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis and inflammation.

HIV/AIDS

Merck Sharp & Dohme patents Gag polyprotein (HIV-1)/protein Pol dimerization inducers

April 28, 2023

Merck Sharp & Dohme Corp. researchers have patented targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers and thus reported to be useful for the treatment of HIV infection.

Neurology/Psychiatric

Merck Sharp & Dohme patents LRRK2 inhibitors for Parkinson’s disease

April 27, 2023

Leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors have been detailed in a recent Merck Sharp & Dohme Corp. patent and reported to be useful for the treatment of Parkinson’s disease, among others.

Neurology/Psychiatric

Merck Sharp & Dohme patents nicotinic α7 receptor positive allosteric modulators

April 14, 2023

Merck Sharp & Dohme Corp. have identified nicotinic α7 receptor positive allosteric modulators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, and schizophrenia.